--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10, ...
Assembly Bio will receive $100 million, $84.8 million upfront payment and a $15.2 million equity investment, from Gilead. Gilead has the right to appoint two individuals to Assembly Bio's board. Get ...
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results